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Chronic kidney disease (CKD) is associated with a high risk
of death from coronary artery disease and may modify the
response to standard cardiovascular therapies. Treatment
of subjects with CKD should ideally be based on evidence
from randomized, clinical trials, but how often subjects with
CKD have been excluded from these trials is uncertain. We
undertook this study in order to quantify how often subjects
with moderate to advanced CKD were excluded from large
cardiovascular trials. MEDLINE and the reference list of
selected articles were searched in order to identify large,
randomized, controlled trials of five different coronary artery
disease therapies published between 1998 and 2005.
Exclusion criteria and reported clinical characteristics of
subjects were abstracted. Rates of exclusion and reporting of
baseline characteristics of study participants were compared
for CKD, diabetes, history of smoking, and hypertension.
Eighty-six trials randomizing 411 653 patients were identified.
More than 80% of trials excluded subjects with end-stage
renal disease and 75.0% excluded patients with CKD.
Subjects with diabetes, hypertension, or a history of smoking
were excluded less than 4% of the time. Baseline renal
function of study participant was reported in only 7% of
trials. Patients with CKD are frequently excluded from
coronary artery disease trials and renal function of
randomized subjects is rarely reported. These findings
reinforce the notion that available data on the treatment of
coronary artery disease in subjects with CKD have significant
limitations and should be generalized to the treatment of
subjects with CKD cautiously.
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Roughly 11% of the US population has chronic kidney
disease (CKD),1 and by 2030 there will be more than two
million people with end-stage renal disease (ESRD) and
many times that number with moderate impairment of
kidney function.2 Both ESRD and moderate CKD are
associated with high risks of death from coronary artery
disease.3,4 This risk is not fully explained by traditional
cardiovascular risk factors, and the usual relationship of these
risk factors to cardiovascular outcomes is significantly altered
in the setting of renal failure.3–10
Given the unique features of coronary artery disease in
CKD it is possible that established cardiovascular therapies,
or at least those tested solely in populations with normal
renal function, will prove to be less effective in patients with
CKD than in those with normal renal function. Alternatively,
the high baseline risk in patients with CKD could magnify
the absolute benefit of treatment with standard cardiovas-
cular therapies. Indeed, the importance of specifically testing
established cardiovascular therapies in subjects with CKD
was highlighted by the negative findings of two recent trials
that randomized patients with advanced kidney disease to
treatment with statins vs placebo.11,12 Thus, both theoretical
considerations and the available randomized evidence suggest
that uncertainty about the appropriate role for standard
therapies in subjects with CKD is warranted when those
therapies have not been broadly tested on subjects with
impaired kidney function.
How often renal function has been used to exclude
participation in clinical trials and whether renal function is
used to exclude participation in clinical trials more frequently
than other high-risk conditions have not been systematically
studied or quantified. We undertook the current study in
order to systematically determine whether subjects with
moderate CKD or dialysis-dependent ESRD are excluded
from enrolment in large, coronary artery disease trials more
frequently than subjects with other high-risk conditions such
as diabetes, hypertension, or smoking and to compare the
extent to which those trials report on the presence of these
conditions at baseline.
RESULTS
A total of 3076 articles were identified via electronic and
hand searches. As shown in Figure 1, 86 trials randomizing
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411 653 subjects met the inclusion criteria and were selected
for further analysis. Twenty-one trials randomized patients
to GPIIb–IIIa inhibitors, 15 to oral anti-platelet agents, 30
to statins, seven to beta blockers, and 18 to percutaneous
coronary intervention or devices. Five trials randomized
patients to more than one of these interventions (Table 1).
Subjects with chronic renal insufficiency or ESRD were
most likely to be excluded from trials of statins or GIIb/IIIa
inhibitors – 90% (95% confidence interval (CI): 73.5–97.9) of
statin trials and 85.7% (95% CI: 63.7–97.0) GIIb/IIIa trials
excluded subjects with either condition. Trials of oral anti-
platelet agents included subjects with CKD more frequently,
but approximately half used CKD as an exclusion criteria –
60% (95% CI: 32.3–83.7) excluded subjects with ESRD and
46.6% (95% CI: 16.3–67.7) excluded subjects with earlier
stages of CKD.
Exclusion of patients with CKD was typically based on the
serum creatinine. In only five trials was the threshold based
on estimated GFR or creatinine clearance. A threshold
creatinine clearance of 30 cm3/min or less was used in five
trials. Two trials used a threshold creatinine below 1.5 mg/dl,
35 trials used a threshold between 1.5 and 2.0 mg/dl, and 18
trials used a threshold creatinine above 2.0 mg/dl.
All five types of trials were unlikely to report the baseline
renal function or frequency of renal impairment in trial
participants. This information was reported most frequently
in trials of beta blocking agents, but was still available
only 28.6% (95% CI: 3.7–70.9) of the time in this setting.
Results from the individual trials are summarized in
Tables 2–6.
Out of 86 trials, 69 (80.6%, 95% CI: 70.2–88.0) excluded
patients with ESRD and 64 (74.4, 95% CI: 63.9–88.2)
excluded patients with moderate to severe renal insufficiency.
Patients with diabetes, hypertension, or a history of smoking
were rarely excluded from participation in trials. Only three
studies (3.5%, 95% CI: 0.7–9.8) excluded patients with
diabetes and no study excluded patients with hypertension or
a history of smoking (Po0.0001 for all comparisons, Table 1
and Figure 2).
The percentage of patients with impaired renal function
or the mean baseline serum creatinine of randomized
patients was reported by only six of 86 studies (7.0, 95%
CI: 2.6–14.6). The percentage of patients with hypertension
(or mean baseline blood pressure), diabetes, or a history of
smoking was all reported significantly more frequently
(Po0.0001 for all comparisons). Baseline blood pressure
and smoking history were each recorded in 70 of 86 (81.4,
95% CI: 71.6–89.0) studies. The baseline percentage of
subjects with diabetes was reported in 75 out of 83 studies
(90.4%, 95% CI: 81.9–95.7) that included diabetic patients,
Figure 3.
Search strategy and results
Medline search
3065 citations
Hand search of reference lists
11 citations
3076 citations
2372 discarded based on title
720 citations examined in detail
634 Discarded
86 trials in final analysis
Not population of interest − 67
Not end point of interest − 15
Non randomized − 12
Non English − 2
Not intervention of interest  − 33
< 1000 randomized patients  − 387
Secondary analysis/duplicate publication − 118
Figure 1 | Search strategy and identification of trials for inclusion in analysis.
Table 1 | Exclusion of patients with renal disease according
to trial intervention
Intervention
Number
of trials
Number excluding
subjects with
ESRD (%)
Number excluding
subjects with renal
insufficiency (%)
Anti-platelet agents 15 9 (60.0) 6 (46.6)
Beta blocker 7 4 (57.1) 4 (57.1)
GIIb/IIIa inhibitor 21 18 (85.7) 18 (85.7)
Percutaneous
interventions
18 14 (77.7) 11 (61.1)
Statin 30 27 (90.0) 27 (90.0)
Totala 86 69 (80.2) 64 (74.4)
aFive trials randomized subjects to more than one of these therapies leaving 86
unique trials.
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DISCUSSION
We systematically reviewed the reports of large, randomized
coronary artery disease trials published between 1998 and
2005 to assess whether these trials exclude patients with
moderate or dialysis-dependent CKD more frequently than
they exclude subjects with other cardiovascular risk-factors.
We found that more than 80% of trials exclude patients with
ESRD and nearly 75% exclude patients with moderate renal
insufficiency whereas subjects with other common risk
factors for cardiovascular disease are excluded only rarely.
Further, we found that fewer than 10% of trials provide
information on baseline serum creatinine. Data on the
Table 2 | Trials of GIIb/IIIa inhibitors
Trials Intervention
ESRD
excluded
Exclusion
creatinine (mg/dl)
Other
conditions
excluded
Renal
function
reported
All other
conditions
reported
ASSENT-326 Tenecteplase+enoxaparin, heparin or,
abciximab+heparin
Y 42.5(male)42.0 (female) N N Y
BRAVO27 Lotrafiban vs placebo Y CrClo30 N N Y
CADILLAC28 Abciximab vs placebo Y 42.0 N N Y
EPISTENT29 Stent vs angioplasty abciximab vs placebo N NA N N Y
ESPRIT30 Eptifibatide vs placebo Y 44.0 N N Y
EXCITE31 Xemilofiban vs placebo Y 41.5 N N S, H
GUSTO IV-ACS32 Abciximab vs placebo Y 41.5 N N Y
GUSTO V33 Reteplase vs reteplase+abciximab N NA N N Y
ISAR-REACT34 Abciximab vs placebo N NA N N Y
OPUS-TIMI 1635 Orbofiban vs placebo Y 41.6 N Y H
PARAGON36 Lamifiban vs placebo Y 42.0 N N Y
PARAGON -B37 ASA vs coumadin vs placebo Y CrClo30 N N Y
PRISM38 Tirofiban vs heparin Y 42.5 N N Y
PRISM-PLUS39 Tirofiban vs tirofiban+heparin vs heparin Y 42.5 N N Y
PURSUIT40 Eptifibatide vs placebo Y 42.0 N N Y
REPLACE-241 Heparin+GIIb/IIIa inhibitor vs bivalirudin Y 44.0 N N Y
Second SYMPHONY42 Sirafiban+aspirin vs sirafiban vs aspirin Y 41.5 N Y Y
SYMPHONY43 ASA vs sibrafiban Y 41.5 N N Y
TARGET44 Abciximab vs tirofiban Y 42.5 N N Y
TETAMI45 Enoxaparin vs enoxaparin+tirofiban vs
heparin+tirofiban vs heparin
Y CrClo30 N N Y
ASA, aspirin; CrCl, creatinine clearance; D, diabetic patients excluded or percent of patients with diabetes not reported; ESRD, end-stage renal disease; H, hypertension
excluded or percent of patients with hypertension not reported; N, no; NA, not applicable; S, smokers excluded or percent of smokers not reported; Y, yes.
Note: To convert serum creatinine in mg/dl to mmol/l multiply by 88.4.
Table 3 | Interventional trials
Trial Intervention
ESRD
excluded
Exclusion
creatinine
(mg/dl)
Other
conditions
excluded
Renal
function
reported
All other
conditions
reported
ARTS46 Stent vs CABG Y 41.8 N N Y
ASCENT47 Stent vs stent N NA N N H
CADILLAC28 Stent vs angioplasty Y 42.0 N N Y
CONSERVE48 Low pressure vs conventional stent N NA N N Y
DANAMI 249 Angioplasty vs thrombolysis Y 42.8 N N Y
DELIVER50 Paclitaxel-coated vs bare metal stent Y 42.5 N N Y
EPISTENT29 Stent vs angioplasty N NA N N Y
FRISC II51 Invasive vs conservative Y 41.8 N N Y
Kastrati et al.52 Stent vs stent N NA N N Y
Mauri et al.53 Cutting baloon vs stent Y 42.0
RITA 154 PTCA vs CABG Y NA N N S, H
RITA 255 PTCA vs CABG Y NA N N S, H
RITA 356 Early vs symptom-driven angiography Y NA N N S
SCORES57 Self expanding vs balloon expanding stents Y 41.4 N N Y
SIRIUS58 Sirolimus-coated vs bare metal stent Y 43.0 N N Y
Stent-PAMI59 Stent vs angioplasty Y 42.5 N N S, H
TACTICS-TIMI-1860 Invasive vs conservative Y 42.5 N N S, H
Taxus-IV61 Paclitaxel-coated vs bare metal stent Y 42.0 N N Y
CABG, coronary artery bypass grafting; CrCl, creatinine clearance; D, diabetic patients excluded or percent of patients with diabetes not reported; ESRD, end-stage renal
disease; H, hypertension excluded or percent of patients with hypertension not reported; N, no; NA, not applicable; PCTA, percutaneous trans coronary angioplasty; S,
smokers excluded or percent of smokers not reported; Y, yes.
Note: To convert serum creatinine in mg/dl to mmol/l multiply by 88.4.
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Table 4 | Beta blockers
Trial Intervention
ESRD
excluded
Exclusion
creatinine
(mg/dl)
Other
conditions
excluded
Renal
function
reported
All Other
conditions
reported
CAPPP62 Captopril vs diuretic or beta blocker Y 41.7 N Y Y
CONVINCE63 Verapamil vs atenolol or hydrochlorothiazide Y 42.0 N N Y
CAPRICORN64 Carvedilol vs placebo N NA N N Y
LIFE65 Losartan vs atenolol Y 41.8 N N Y
JBCMI66 Beta blocker vs calcium channel blocker Y ‘Severe renal
insufficiency’
N N Y
NORDIL67 Diltiazem vs beta blockers or diuretics N N N Y Y
STOP-Hypertension 268 ACE inhibitor or calcium channel blocker vs
diuretic or beta blocker
N N N N Y
ACE, angiotensin-converting enzyme; CrCl, creatinine clearance; D, diabetic patients excluded or percent of patients with diabetes not reported; ESRD, end-stage renal
disease; H, hypertension excluded or percent of patients with hypertension not reported; N, no; NA, not applicable; S, smokers excluded or percent of smokers not reported;
Y, yes;
Note: To convert serum creatinine in mg/dl to mmol/l multiply by 88.4.
Table 5 | Statin trials
Trial Intervention
ESRD
excluded
Exclusion
creatinine (mg/dl)
Other
conditions
excluded
Renal
function
reported
All other
conditions
reported
ALERT11 Fluvastatin vs placebo Y CrClo20 N N Y
ALLHAT-LLT69 Pravastatin vs placebo Y 42.0 N N Y
ALLIANCE70 Atorvastatin vs usual care Investigator
discretion
Investigator discretion N N y
AFCAPS/TexCAPS71 Lovastatin vs placebo Y Investigator discretion N N Y
ASCOT-LLA72 Atorvastatin vs placebo Y 42.2 N Y Y
Atorvastatin Comparitive
Cholesterol Efficacy73
Atorvastatin vs fluvastatin
vs lovastatin vs pravastatin
Y 42.0 N N S, D, H
A to Z74 Aggressive vs conservative simvastatin Y 42.0 N N Y
Bays, et al.75 Vytorin vs ezetimibe or simvastatin N NA N N S, D, H
Bruckert, et al.76 Fluvastatin vs placebo Y CrClo30 N N Y
CARDS77 Atorvastatin vs placebo Y 41.6 N Y Y
Cerivastatin Pivotal Trial78 High dose cerivasatin vs low
dose vs placebo
Y Significant abnormality D N Da
CHALLENGE79 Atovastatin vs simvastatin Y 42.0 N N H
Dujovne, et al.80 Cerivastatin vs pravastatin Y 42.0 D N Da, H
Discovery81 Atorvastatin vs rosuvastatin Y 42.5 N N Y
FLARE82 Fluvastatin vs placebo N N N N Y
GREACE83 Atovastatin vs usual care Y 41.3 N Y S
Heart Protection Study84 Simvastatin vs placebo Y 42ULN N N S
Kyushu Lipid Intervention85 Pravastatin vs placebo Y 42.0 N N Y
Lipid Intervention in Kyoto86 Pravastatin vs conventional
Lipid-lowering drugs
Y ‘Severe’ N N D, H
LIPID87 Pravastatin vs placebo Y 41.8 N N Y
LIPS88 Fluvastatin vs placebo Y 41.8 N N Y
MIRACL89 Atorvastatin vs placebo Y N N N Y
MERCURY I90 Rosuvastatin vs atorvastatin
vs simvastatin
vs pravastatin
Y 42.5 N N S, D, H
Olsson, et al.91 Extended release fluvastatin
vs immediate release
Y 41.5 D N S, Da, H
PACT92 Pravastatin vs placebo Y ‘Severe renal disease’ N N H
PaCT93 Pravastatin vs cholestyramine N N N N Y
PROSPER94 Pravastatin vs placebo Y 42.3 N N Y
STELLAR95 Rosuvastatin vs atorvastatin
vs simvastatin vs pravastatin
Y 42.0 N N H, S
TARGET TANGIBLE96 Atorvastatin vs simvastatin Y 41.8 N N Y
TIMI-2297 Pravastatin vs atorvastatin Y 42.0 N N Y
CrCl, creatinine clearance; D, diabetic patients excluded or percent of patients with diabetes not reported; ESRD, end-stage renal disease; H, hypertension excluded or percent
of patients with hypertension not reported; N, no; NA, not applicable; S, smokers excluded or percent of smokers not reported; ULN, upper limit of normal; Y, yes.
Note: To convert serum creatinine in mg/dl to mmol/l multiply by 88.4.
aPatients with diabetes excluded from participation.
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estimated glomerular filtration rate or creatinine clearance of
randomized subjects, which are better markers of renal
function than serum creatinine alone, are provided even less
frequently. Our results thus demonstrate that among
common cardiovascular risk factors, there is a unique failure
of large cardiovascular trials to produce data on the
treatment of cardiovascular disease in the setting of moderate
or advanced CKD.
This failure to test coronary artery disease therapies in
patients with advanced renal insufficiency has significant
implications when considered in light of elevated cardiovas-
cular mortality rates in subjects with CKD,4 the fact that as
many as 50% of subjects admitted with a myocardial
infarction have stage 3 or worse CKD13 and the common
failure to administer standard cardiovascular therapies to
patients with CKD even when they are diagnosed with
myocardial infarction.14–16 Because there is insufficient
randomized evidence on the effectiveness of typical therapies
in subjects with CKD, it is difficult to know whether this low
use represents appropriate concern about the use of
unproven therapies, appropriate response to comorbidity in
patients with CKD,17 or whether it partially explains the high
rates of cardiovascular morbidity and mortality in the CKD
population.5–8,18
More importantly, there is a growing body of literature
suggesting that standard treatment strategies may act
differently in patients with and without CKD 14,15,19 – a
concept reinforced by two trials of statins that were
conducted in populations with CKD.11,12 Available evidence,
including the present study, thus suggests that the general
standard of care for coronary artery disease should be
extrapolated to subjects with CKD cautiously, except in those
rare cases where subjects with CKD have been randomized in
significant numbers.
Table 6 | Non-GIIb/IIIa oral anti-platelet therapy
Trial Intervention Excluded
Creatinine
(mg/dl)
Conditions
Excluded
Function
Reported
Other
Conditions
Reported
CLARITY-TIMI 2898 Clopidogrel vs placebo Y 42.5 N N Y
CLASSICS99 3 regimens of plavix+ASA Y 42.0 N N Y
CREDO100 Clopidogrel vs placebo Y 43.0 N N Y
CURE101 Clopidogrel vs placebo N NA N N Y
HOT102 ASA vs Placebo/vitamin E. vs Placebo N N N Y Y
Primary Prevention Project103 ASA vs Placebo/vitamin E. vs Placebo N NA N N Y
Second SYMPHONY42 ASA vs sibrafiban+ASA vs sibrafiban Y 41.5 N Y Y
STAMI104 Ticlopidine vs ASA Y 41.5 normal N N Y
STARS105 ASA vs ASA+coumadin vs ASA+ticlopidine N NA N N Y
SYMPHONY43 ASA vs sibrafiban Y 41.5 N N Y
Taniuchi et al.106 Ticlopidine vs clopidogrel N NA N S
TIM107 Triflusal vs ASA Y Investigator discretion N N Y
TPT108 ASA vs coumadin vs placebo Y Investigator discretion N N D
WARIS II109 ASA vs coumadin vs coumadin+ASA N NA N N Y
Women’s Health Study110 ASA vs placebo N NA N N Y
ASA, aspirin; CrCl, creatinine clearance; D, diabetic patients excluded or percent of patients with diabetes not reported; H, hypertension excluded or percent of patients with
hypertension not reported; N, no; NA, not applicable; S, smokers excluded or percent of smokers not reported; Y, yes.
Note: To convert serum creatinine in mg/dl to mmol/l multiply by 88.4.
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Figure 2 | Percent of cardiovascular trials excluding subjects
with ESRD, CKD, hypertension, diabetes, or smoking from
participation. *Po0.0001 for comparisons with diabetes,
hypertension, and smoking.
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Figure 3 | Percent of cardiovascular trials reporting on the
presence of CKD, hypertension, diabetes, or smoking at baseline.
*Po0.0001 for comparisons with diabetes, hypertension, and
smoking.
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This failure of large coronary artery disease trials to
include patients with CKD is particularly concerning when
one considers that the number of randomized controlled trail
published in nephrology is low and compounded by poor
quality and reporting20 and thus unlikely to provide
definitive answers on cardiovascular care in this population.
Our findings, highlight and quantify the limitations of
current evidence on the treatment of cardiovascular disease
in subjects with CKD and provide a strong rationale for
including greater numbers of subjects with CKD in future
trials or for specifically targeting subjects with CKD as the
population for future trials of standard and emerging
therapies of coronary artery disease. Finally, the reliance of
serum creatinine as the measure of renal function in the
majority of studies we analyzed highlights the need to
educate cardiovascular trialists on the availability of better
estimates of renal function for use during randomization and
follow-up of patients.
Our findings should be interpreted within the context of
our methodology. Our search was limited to peer-reviewed
trials randomizing at least 1000 patients to five different
therapies. We cannot rule out the possibility that small trials
or trials of other therapies are more likely to include patients
with kidney disease. However, our results were consistent
across a broad array of both medical and interventional
therapies. Furthermore, large trials with power to provide
definitive answers to clinical questions provide important
data that profoundly influences evidenced-based medical
practice. The clinical importance of our findings would be
only slightly diminished in the event that small or
unpublished trials are more likely to enrol subjects with
kidney disease than the trials we studied.
We did not directly assess whether separate, smaller trials
are being conducted in patients with renal insufficiency.
Nevertheless, our search strategy incidentally identified only a
single, randomized trial published between 1998 and March
2005 that tested whether a drug or device prevents
myocardial infarction or cardiovascular death in patients
with renal insufficiency.21
Finally, the low rate of reporting on the baseline renal
function of trial participants that we found does not account
for the possibility of subsequent publication of subgroup
analyses of the treatment effect in subjects with vs without
renal insufficiency. Such publications can partially mitigate
the import of an initial failure to report the percent of
subjects with renal disease, but that initial failure nevertheless
reflects a markedly different approach by clinical trialists
towards CKD as a coronary disease risk factor than they have
for other common conditions such as hypertension, diabetes,
and smoking. Given the high risk of cardiovascular events in
subjects with CKD and high frequency of this condition in
the general population, we find this practice puzzling.
Additionally, subgroup analyses, particularly if not pre-
specified, are susceptible to false-positive and false-negative
findings.22 Further, their publication is frequently delayed by
several years compared to the initial publication of the overall
results. For both reasons, having enough information to draw
conclusions about a trial’s relevance to subjects with CKD at
the time of initial publication would be preferable to current
practices.
An important question raised by our findings is whether
there are sufficiently compelling reasons to exclude patients
with CKD despite the clear need for better data about this
group. Inclusion of a new subgroup of patients in
cardiovascular trials might skew the overall results or the
power to detect a therapeutic effect by altering the rate of
cardiovascular events, the case-fatality rate, or the frequency
of non-cardiovascular death in the trial cohort, although
stratified randomization or limiting the numbers of rando-
mized patients with a particularly high-risk condition can be
used to mitigate the influence of that condition on trial
results. Moreover, the risk of cardiovascular disease among
patients with moderate renal impairment is actually similar
to the risk among patients with diabetes, smoking, or
hypertension,5–9,18,23 and randomized trials are unlikely to
randomize substantially more patients with moderate or
advanced renal insufficiency than they currently randomize
with diabetes or hypertension. The risk profile is significantly
different in patients with ESRD where the mortality rate is
significantly higher than in the general population.24
However, roughly half of deaths in patients with ESRD are
due to cardiovascular disease,25 and any loss of power owing
to an increased rate of non-cardiovascular deaths might well
be neutralized by a concurrent increase in the rate of
cardiovascular morbidity.
A reduction in the glomerular filtration rate can alter the
safety profile of some drugs and devices, and might be an
appropriate reason to exclude patients from participation in
trials, especially phase I and phase II trials. However, none of
the therapies we studied is contraindicated in patients with
renal insufficiency. Indeed, a high proportion of trials of beta
blockers, statins, and anti-platelet therapies excluded patients
with renal insufficiency despite the widespread clinical use of
these agents in studies on patients with ESRD.14
Finally, if the altered epidemiology and pathophysiology
of cardiovascular disease in patients with renal disease10
confers resistance to standard therapies, then the inclusion
of patients with renal insufficiency in trials will decrease
the observed treatment effect and bias towards the null
hypothesis. Belief in this theory may partially explain why
patients with renal disease are so frequently excluded
from cardiovascular trials, but it remains an unproven
hypothesis that at a minimum deserves to be tested in
clinical trials.
A significant and growing minority of people in this
country has CKD. They suffer from an increased risk of
developing and dying from coronary artery disease and
whether they respond differently to cardiovascular therapies
is uncertain. It is therefore crucial that we advance our
knowledge of how to treat and prevent cardiovascular disease
in this population. Unfortunately, large, contemporary trials
have largely ignored these patients despite compelling reasons
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to increase our understanding of the unique features of their
disease. Government and industry-funded trials must enrol
greater numbers of patients with impaired kidney function in
trials or should specifically target trials towards the CKD
population so that we can provide the best possible
cardiovascular care for this crucial population.
MATERIALS AND METHODS
Definitions
Our objective in this study was to understand how contemporary
clinical research applies to patients with renal disease. Because small
trials or trials published only in abstract form are less likely to
influence clinical practice or lead to Food and Drug Administration
approval of new drugs and devices than larger trials that have been
published in peer-reviewed journals, we restricted our analysis to
published trials that randomized at least 1000 subjects. We looked at
five different interventions selected because as a group they
represent the standard therapies now used for the treatment of
coronary artery disease. Trials randomizing subjects to beta-
blockers, GIIb/IIIa inhibitors, non-GIIb/IIIa oral anti-platelet
agents, HMG-CoA reductase inhibitors, or a percutaneous coronary
intervention or coronary stents were included in this study. In order
to examine contemporary practices, we restricted our analysis to
trials whose principal results were published in peer-reviewed
journals between January 1998 and March 2005.
Trials that studied the aforementioned agents for purposes other
than the treatment of coronary artery disease were excluded from
further analysis. Thus, trials were included when at least one of the
following conditions was met: (a) ischemic coronary artery disease
was a prerequisite for randomization; (b) the primary end point
assessed the occurrence of new or recurrent coronary artery disease
that included myocardial infarction, coronary revascularization, and
cardiovascular death; and (c) the primary end point assessed the effect
of a medication on the low-density lipoprotein cholesterol concen-
tration. The last criterion was chosen because low-density lipoprotein
cholesterol lowering has been widely accepted as a valid surrogate end
point for statin therapy, is widely used to guide the use of statins, and
has been used to justify the approval of new statin medications.
We chose not to study trials of angiotensin-converting enzyme
inhibitors) and angiotensin receptor blockers. Angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers have recently
emerged as important agents in the treatment and prevention of
cardiovascular disease. However, in contrast to the other therapies we
studied, the use of angiotensin-converting enzyme inhibitors and/or
angiotensin receptor blockers forms the standard of care in the
therapy of CKD. These agents are routinely prescribed to reduce
proteinuria and slow progression of renal disease in patients with
CKD regardless of their role in the treatment of cardiovascular
disease. Thus, whereas it would have been interesting to study trials of
these medications, we felt that the clear nephrologic indications for
their use mitigated the clinical impact of exclusion of patients with
CKD from cardiovascular trials of angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers.
Search strategy
MEDLINE searches using the PubMed interface were conducted for
the period between January 1998 and March 2005. Search terms
included the following MeSH headings: beta blocker, platelet
glycoprotein GPIIb–IIIa complex, HMG-CoA reductase inhibitors,
angioplasty, stent, aspirin, and ticlopidine. Additional search terms
included the generic names of individual beta blockers, GIIb/IIIa
inhibitors, statins, and anti-platelet agents. The following limits were
used: English-language; randomized, controlled trial; and adults
greater than 19 years old. The reference lists of selected trials were
also manually reviewed in order to identify additional studies.
Eligibility for inclusion was determined after review of titles,
abstracts or, where necessary, the full manuscript.
Data abstraction and analysis
For each trial, the exclusion criteria were abstracted from the
published reports. Exclusion of subjects with CKD was
defined as the use of ‘renal insufficiency’ or a threshold of
serum creatinine, blood urea nitrogen, or creatinine clearance
to exclude subjects from randomization. Authors were
contacted for clarification of the exclusion criteria when the
published reports were unclear or when individual investi-
gators were allowed to exclude patients based on the presence
of conditions they believed would compromise life expec-
tancy or a subject’s ability to comply with the assigned
treatment. In the event that the authors could not to be
reached for clarification, trials were considered to have
included patients with CKD. The proportion of studies
excluding patients with moderate CKD or dialysis-dependent
CKD was calculated from these data.
For comparative purposes, we also assessed how fre-
quently subjects with a clinical history of diabetes, smoking,
or hypertension – other common risk factors for cardio-
vascular disease – were excluded from trial participation. In
addition, we abstracted whether studies reported the baseline
percentage of patients with diabetes, a history of smoking,
CKD, or hypertension. Reporting on the mean baseline
serum creatinine was considered equivalent to reporting on
the number of subjects with CKD. Reporting mean baseline
blood pressure was considered equivalent to reporting on the
percentage of subjects with diagnosed hypertension.
Proportions were compared using an exact binomial test.
Po0.05 was considered significant. All calculations were
performed in Stata version 8.0 (Stata Corporation, College
Station, TX, USA).
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